BeOne Medicines AG
HKEX:6160
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
BeOne Medicines AG (6160) under the Base Case is HKD per share.
Compared with the current market price of 247.4 HKD, the stock appears .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years.
Create a free account · No card needed
Fundamental Analysis
What BeOne Medicines Does
BeiGene is a cancer drug company that discovers, develops, manufactures, and sells medicines for oncology. Its best-known products are targeted therapies and immunotherapies used to treat different kinds of blood cancers and solid tumors. The company also runs clinical trials to find new drug candidates and expand the uses of its existing medicines.
- Headquarters
- Switzerland CH
- Employees
- 12 000
- IPO date
- Mar 2, 2016
Continue Research
Decided on BeOne Medicines? Get an email when BeOne Medicines AG reaches the price you’d buy at. Free with an account.
Other BeOne Medicines listings
What is the Intrinsic Value of one BeOne Medicines AG stock?
The intrinsic value for
BeOne Medicines AG (6160) under the Base Case is HKD.
Is BeOne Medicines AG stock undervalued or overvalued?
Compared with the current market price of 247.4 HKD, the stock appears .